Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists / L. Peverelli, A. De Rosa, E. Domina, P. Ciscato, G. Sita, D. Velardo, G.P. Comi. - In: JOURNAL OF NEUROMUSCULAR DISEASES. - ISSN 2214-3599. - 7:4(2020), pp. 511-514.
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists
L. PeverelliPrimo
;G.P. ComiUltimo
2020
Abstract
Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.
| File | Dimensione | Formato | |
|---|---|---|---|
|
peverelli2020 AIR.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
313.09 kB
Formato
Adobe PDF
|
313.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
